Naftopidil DiHCl

Research use only, not for human use.

Naftopidil DiHCl is a selective 5-HT1A and α1-adrenergic receptor antagonist with IC50 of 0.1 μM and 0.2 μM, respectively.

Naftopidil DiHCl is a selective 5-HT1A and α1-adrenergic receptor antagonist with IC50 of 0.1 μM and 0.2 μM, respectively.

Naftopidil dihydrochloride suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.Naftopidil dihydrochloride (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC.Naftopidil dihydrochloride (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.Cell Proliferation Assay Cell Line:PCa cells, PrSC Concentration:10 μM (PCa cells); 0.1 μM, 1 μM, 10 μM (PrSC)Incubation Time:3 days Result:Exhibited growth inhibitory effects on PCa cells and PrSC in dose-dependent manners.Western Blot Analysis Cell Line:PCa cells, PrSC Concentration:50 μM (E9 cells), 25 μM (PrSC)Incubation Time:48 hours Result:Increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.

Naftopidil dihydrochloride (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model. Animal Model:Male athymic mice(7-8 weeks), with E9+PrSC xenograft Dosage:10 mg/kg Administration:Oral administration, daily, for 28 days Result:Decreased tumor weights.

——

Metabolic Enzyme/Protease

Lipase

5-HT1A| α1-adrenergic receptor

Others-Field

——

57149-08-3

465.41

C24H28N2O3·2HCl

>98% (HPLC)

——

Cl.Cl.COC1=CC=CC=C1N1CCN(CC(O)COC2=C3C=CC=CC3=CC=C2)CC1

——

(-20℃)

With Ice Pack

≥ 2 years